Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209416 | 0.85 | VNN1 (0.49) | MAOBMAOATAAR1MAPK8 | |
| SCHEMBL6509671 | 0.85 | ALDH1A1 (0.46) | — | |
| SCHEMBL6864466 | 0.83 | TAAR1 (0.50) | MAOBIDO1AGXTTAAR1SLC1A1 | |
| SCHEMBL3025521 | 0.83 | TAAR1 (0.50) | MAOBIDO1AGXTMAOATAAR1 | |
| SCHEMBL9113 | 0.82 | AKR1B1 (0.58) | TAAR1SLC1A1 | |
| SCHEMBL8498964 | 0.81 | VNN1 (0.48) | MAOBTAAR1RIPK1SLC1A1CASP3 | |
| SCHEMBL2290 | 0.81 | ALDH1A1 (0.60) | MAOBMAOATAAR1CASP3CASP7 | |
| SCHEMBL2304146 | 0.80 | AGXT (0.57) | AGXT | |
| SCHEMBL1149255 | 0.80 | TAAR1 (0.47) | IDO1AGXTTAAR1SLC1A1CASP3 | |
| Hydrochloric Acid SCHEMBL2531929 | 0.80 | AKR1B1 (0.56) | IDO1AGXTTAAR1SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114950159-B | Preparation method of aromatic polymer separation membrane based on super acid catalysis | 南京工业大学 | 2023-06-06 | — | — | CN | claimed |
| CN-120058445-A | Method for generating aryl phenol compound by hydroxylation of uranium photocatalytic aryl fluorine compound and application of method | 华东师范大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-118879823-A | Synthesis method of (R) -3-halogenated phenylpropanol | 四川新迪生物制药有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12084436-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-10 | — | — | US | disclosed |
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-10 | — | — | US | disclosed |
| US-20240226305-A1 | COMPOUNDS FOR TREATMENT OF TYPE 2 DIABETES | ELMALEH DAVID R (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023114379-A1 | PLPRO INHIBITORS | HUAHAI US INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-4132938-A1 | SUBSTITUTED THIAZOLOPYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-02-15 | — | — | EP | disclosed |
| WO-2003080625-A1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | disclosed |
| CN-1433972-A | Process for degrading organic fluoride from waste water by photocatalysis | JIANGSU ACADEMY OF ENVIRONMENT (CN) | 2003-08-06 | — | — | CN | disclosed |
| EP-1261600-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | disclosed |
| WO-2001058890-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
| US-4487969-A | DIAZOTIZATION OF M-AMINOACETOPHENONE FOLLOWED BY HEAT DECOMPOSITION | OLIN CORPORATION (US) | 1984-12-11 | — | — | US | disclosed |
| EP-0105641-A1 | Production of m-fluoroacetophenone | OLIN CORPORATION (US) | 1984-04-18 | — | — | EP | disclosed |
| US-4393004-A | DUIRETICS | AMERICAN CYANAMID COMPANY (US) | 1983-07-12 | — | — | US | disclosed |
| US-4340734-A | DIURETICS | AMERICAN CYANAMID COMPANY (US) | 1982-07-20 | — | — | US | disclosed |
| US-4325955-A | DIURETICS | AMERICAN CYANAMID COMPANY (US) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | MAOB 4301/4885IDO1 3852/4885AGXT 4004/4885 |
| US-12084436-B2 | Heterocyclic compound | HDAC1, HDAC5, HDAC6 | MAOB 340/4885IDO1 1525/4885AGXT 1755/4885 |
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | MAOB 337/4885IDO1 238/4885AGXT 989/4885 |
| US-20240226305-A1 | COMPOUNDS FOR TREATMENT OF TYPE 2 DIABETES | SLC5A2, GPR119, GLP1R | MAOB 562/4885IDO1 1541/4885AGXT 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.